The authors of the correspondence read with interest the article by Marco P. Bonac and colleagues on the STRIDE study. A study showed that the GLP-1 receptor agonist semaglutide improved walking distance by 13% in patients with peripheral artery disease and type 2 diabetes.[1] The authors agree that semaglutide should have a place in the treatment of peripheral artery disease in patients with type 2 diabetes. The STRIDE trial was a randomised, placebo-controlled, double-blind phase 3b study in 972 patients with type 2 diabetes and Fontaine stage IIa peripheral arterial obliterating disease (PAOD) with claudication.[1] It tested the addition of subcutaneous semaglutide 1 mg once weekly to standard treatment versus placebo.[1] In an exploratory analysis, the composite outcome of need for rescue treatment and all-cause mortality was reduced by more than half (HR 0.46; 95% CI 0.24–0.85) in patients with semaglutide.[1]